{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:08Z","timestamp":1787020688122,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004635","name":"Fru Berta Kamprads Stiftelse","doi-asserted-by":"publisher","award":["FBKS 2020-19-301"],"award-info":[{"award-number":["FBKS 2020-19-301"]}],"id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prescribed radiation dose to patients with oropharyngeal squamous cell carcinoma (OPSCC) is standardized, even if the prognosis for individual patients may differ. Easy-at-hand pre-treatment risk stratification methods are valuable to individualize therapy. In the current study we assessed the prognostic impact of primary tumor volume for p16-positive and p16-negative tumors and in relationship to other prognostic factors for outcome in patients with OPSCC treated with primary radiation therapy (RT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Five hundred twenty-three OPSCC patients with p16-status treated with primary RT (68.0\u00a0Gy to 73.1\u00a0Gy in 7\u00a0weeks, or 68.0\u00a0Gy in 4.5\u00a0weeks), with or without concurrent chemotherapy, within three prospective trials were included in the study. Local failure (LF), progression free survival (PFS) and overall survival (OS) in relationship to the size of the primary gross tumor volume (GTV-T) and other prognostic factors were investigated. Efficiency of intensified RT (RT with total dose 73.1\u00a0Gy or given within 4.5\u00a0weeks) was analyzed in relationship to tumor volume.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The volume of GTV-T and p16-status were found to be the strongest prognostic markers for LF, PFS and OS. For p16-positive tumors, an increase in tumor volume had a significantly higher negative prognostic impact compared with p16-negative tumors. Within a T-classification, patients with a smaller tumor, compared with a larger tumor, had a better prognosis. The importance of tumor volume remained after adjusting for nodal status, age, performance status, smoking status, sex, and hemoglobin-level. The adjusted hazard ratio for OS per cm\n                      <jats:sup>3<\/jats:sup>\n                      increase in tumor volume was 2.3% (95% CI 0\u20134.9) for p16-positive and 1.3% (95% 0.3\u20132.2) for p16-negative. Exploratory analyses suggested that intensified RT could mitigate the negative impact of a large tumor volume.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Outcome for patients with OPSCC treated with RT is largely determined by tumor volume, even when adjusting for other established prognostic factors. Tumor volume is significantly more influential for patients with p16-positive tumors. Patients with large tumor volumes might benefit by intensified RT to improve survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-022-02074-7","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T06:21:08Z","timestamp":1655187668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy"],"prefix":"10.1186","volume":"17","author":[{"given":"Gabriel","family":"Adrian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Kjell\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Sj\u00f6vall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Zackrisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gebre-Medhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"key":"2074_CR1","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I BF. Global cancer observatory: cancer today. Lyon, France: international agency for research on cancer. Internet. 2018."},{"key":"2074_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T\u00e2n PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24\u201335. https:\/\/doi.org\/10.1056\/NEJMoa0912217.","journal-title":"N Engl J Med"},{"key":"2074_CR3","volume-title":"UICC TNM classification of malignant tumours","author":"J Brierley","year":"2017","unstructured":"Brierley J, Gospodarowicz MWC. UICC TNM classification of malignant tumours. 8th ed. Chichester: Wiley; 2017.","edition":"8"},{"key":"2074_CR4","doi-asserted-by":"publisher","first-page":"104608","DOI":"10.1016\/j.oraloncology.2020.104608","volume":"103","author":"RR Patel","year":"2020","unstructured":"Patel RR, Ludmir EB, Augustyn A, Zaorsky NG, Lehrer EJ, Ryali R, et al. De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials. Oral Oncol. 2020;103:104608. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104608.","journal-title":"Oral Oncol"},{"key":"2074_CR5","doi-asserted-by":"crossref","unstructured":"Saks\u00f8 M, Primdahl H, Johansen J, Nowicka-Matus K, Overgaard J (219) DAHANCA 33: functional image-guided dose-escalated radiotherapy to patients with hypoxic squamous cell carcinoma of the head and neck NCT02976051. Acta Oncol Madr Taylor & Francis 59(2): 1\u20134.","DOI":"10.1080\/0284186X.2019.1695065"},{"key":"2074_CR6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","volume":"31","author":"J-P Machiels","year":"2020","unstructured":"Machiels J-P, Ren\u00e9 Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS\u2013ESMO\u2013ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Elsevier Ltd. 2020;31:1462\u201375. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.011.","journal-title":"Ann Oncol Elsevier Ltd"},{"key":"2074_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.oraloncology.2012.09.014","volume":"49","author":"G Studer","year":"2013","unstructured":"Studer G, Glanzmann C. Volumetric staging in oropharyngeal cancer patients treated with definitive IMRT. Oral Oncol. 2013;49:269\u201376. https:\/\/doi.org\/10.1016\/j.oraloncology.2012.09.014.","journal-title":"Oral Oncol"},{"key":"2074_CR8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.ijrobp.2011.03.029","volume":"82","author":"BH Lok","year":"2012","unstructured":"Lok BH, Setton J, Caria N, Romanyshyn J, Wolden SL, Zelefsky MJ, et al. Intensity-modulated radiation therapy in oropharyngeal carcinoma: Effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys. 2012;82:1851\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.03.029.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2074_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijrobp.2003.08.004","volume":"59","author":"KSC Chao","year":"2004","unstructured":"Chao KSC, Ozyigit G, Blanco AI, Thorstad WL, Deasy JO, Haughey BH, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: Impact of tumor volume. Int J Radiat Oncol Biol Phys. 2004;59:43\u201350. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.08.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2074_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00066-018-1309-z","volume":"194","author":"T Carp\u00e9n","year":"2018","unstructured":"Carp\u00e9n T, Saarilahti K, Haglund C, Markkola A, Tarkkanen J, Hagstr\u00f6m J, et al. Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy. Strahlentherapie und Onkol. 2018;194:759\u201370. https:\/\/doi.org\/10.1007\/s00066-018-1309-z.","journal-title":"Strahlentherapie und Onkol"},{"issue":"Suppl 1","key":"2074_CR11","doi-asserted-by":"publisher","first-page":"E1613","DOI":"10.1002\/hed.24287","volume":"38","author":"KS Davis","year":"2016","unstructured":"Davis KS, Lim CM, Clump DA, Heron DE, Ohr JP, Kim S, et al. Tumor volume as a predictor of survival in human papillomavirus-positive oropharyngeal cancer. Head Neck. 2016;38(Suppl 1):E1613\u20137. https:\/\/doi.org\/10.1002\/hed.24287.","journal-title":"Head Neck"},{"key":"2074_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.radonc.2016.11.008","volume":"121","author":"A Linge","year":"2016","unstructured":"Linge A, Lohaus F, L\u00f6ck S, Nowak A, Gudziol V, Valentini C, et al. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German cancer consortium radiation. Radiother Oncol Elsevier Ireland Ltd. 2016;121:364\u201373. https:\/\/doi.org\/10.1016\/j.radonc.2016.11.008.","journal-title":"Radiother Oncol Elsevier Ireland Ltd"},{"key":"2074_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13014-019-1452-4","volume":"15","author":"L Sch\u00fcttrumpf","year":"2020","unstructured":"Sch\u00fcttrumpf L, Marschner S, Scheu K, Hess J, Rietzler S, Walch A, et al. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group \u201cpersonalized radiotherapy in head and neck cancer.\u201d Radiat Oncol. 2020;15:7. https:\/\/doi.org\/10.1186\/s13014-019-1452-4.","journal-title":"Radiat Oncol"},{"key":"2074_CR14","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1080\/02841860902845839","volume":"48","author":"JP Agarwal","year":"2009","unstructured":"Agarwal JP, Mallick I, Bhutani R, Ghosh-Laskar S, Gupta T, Budrukkar A, et al. Prognostic factors in oropharyngeal cancer analysis of 627 cases receiving definitive radiotherapy. Acta Oncol (Madr). 2009;48:1026\u201333. https:\/\/doi.org\/10.1080\/02841860902845839.","journal-title":"Acta Oncol (Madr)"},{"key":"2074_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/0167-8140(95)01539-S","volume":"35","author":"W Van den Bogaert","year":"1995","unstructured":"Van den Bogaert W, van der Schueren E, Horiot JC, De Vilhena M, Schraub S, Svoboda V, et al. The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors. Radiother Oncol. 1995;35:100\u20136. https:\/\/doi.org\/10.1016\/0167-8140(95)01539-S.","journal-title":"Radiother Oncol"},{"key":"2074_CR16","doi-asserted-by":"publisher","unstructured":"Lassen P, Lacas B, Pignon JP, Trotti A, Zackrisson B, Zhang Q, et al (2018) Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. Radiother Oncol. Elsevier B.V.; 2018;126: 107\u201315 https:\/\/doi.org\/10.1016\/j.radonc.2017.10.018","DOI":"10.1016\/j.radonc.2017.10.018"},{"key":"2074_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0167-8140(91)90184-I","volume":"20","author":"S Dische","year":"1991","unstructured":"Dische S. Radiotherapy and anaemia - the clinical experience. Radiother Oncol. 1991;20:35\u201340. https:\/\/doi.org\/10.1016\/0167-8140(91)90184-I.","journal-title":"Radiother Oncol"},{"key":"2074_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.radonc.2015.09.024","volume":"117","author":"B Zackrisson","year":"2015","unstructured":"Zackrisson B, Kjell\u00e9n E, S\u00f6derstr\u00f6m K, Brun E, Nyman J, Friesland S, et al. Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN trial. Radiother Oncol. 2015;117:99\u2013105. https:\/\/doi.org\/10.1016\/j.radonc.2015.09.024.","journal-title":"Radiother Oncol"},{"key":"2074_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.20.02072","volume":"39","author":"M Gebre-Medhin","year":"2021","unstructured":"Gebre-Medhin M, Brun E, Engstr\u00f6m P, Haugen Cange H, Hammarstedt-Nordenvall L, Reizenstein J, et al. ARTSCAN III: A randomized phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. J Clin Oncol. 2021;39:38\u201347. https:\/\/doi.org\/10.1200\/JCO.20.02072.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2074_CR20","doi-asserted-by":"publisher","first-page":"E473","DOI":"10.1002\/hed.24021","volume":"38","author":"J Sj\u00f6vall","year":"2016","unstructured":"Sj\u00f6vall J, Wahlberg P, Almquist H, Kjell\u00e9n E, Brun E. A prospective study of positron emission tomography for evaluation of neck node response 6 weeks after radiotherapy in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38(Suppl 1):E473\u20139. https:\/\/doi.org\/10.1002\/hed.24021.","journal-title":"Head Neck"},{"key":"2074_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26142","author":"G Adrian","year":"2020","unstructured":"Adrian G, Gebre-Medhin M, Kjell\u00e9n E, Wieslander E, Zackrisson B, Nilsson P. Altered fractionation diminishes importance of tumor volume in oropharyngeal cancer: Subgroup analysis of ARTSCAN-trial. Head Neck. 2020. https:\/\/doi.org\/10.1002\/hed.26142.","journal-title":"Head Neck"},{"key":"2074_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/hed.21459","volume":"33","author":"JL Knegjens","year":"2011","unstructured":"Knegjens JL, Hauptmann M, Pameijer FA, Balm AJ, Hoebers FJ, de Bois JA, et al. Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head Neck. 2011;33:375\u201382. https:\/\/doi.org\/10.1002\/hed.21459.","journal-title":"Head Neck"},{"key":"2074_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-9-23","volume":"9","author":"T Rutkowski","year":"2014","unstructured":"Rutkowski T. The role of tumor volume in radiotherapy of patients with head and neck cancer. Radiat Oncol. 2014;9:1\u20139. https:\/\/doi.org\/10.1186\/1748-717X-9-23.","journal-title":"Radiat Oncol"},{"key":"2074_CR24","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/02841860600815407","volume":"46","author":"G Studer","year":"2007","unstructured":"Studer G, L\u00fctolf UM, El-Bassiouni M, Rousson V, Glanzmann C. Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT. Acta Oncol (Madr). 2007;46:386\u201394. https:\/\/doi.org\/10.1080\/02841860600815407.","journal-title":"Acta Oncol (Madr)"},{"key":"2074_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00066-013-0413-3","volume":"189","author":"G Studer","year":"2013","unstructured":"Studer G, Glanzmann C. Volumetric stratification of cT4 stage head and neck cancer. Strahlentherapie und Onkol. 2013;189:867\u201373. https:\/\/doi.org\/10.1007\/s00066-013-0413-3.","journal-title":"Strahlentherapie und Onkol"},{"key":"2074_CR26","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.ijrobp.2010.10.053","volume":"82","author":"A Strongin","year":"2012","unstructured":"Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, et al. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:1823\u201330. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.10.053.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2074_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/COC.0b013e31826e04d6","volume":"37","author":"PB Romesser","year":"2014","unstructured":"Romesser PB, Qureshi MM, Subramaniam RM, Sakai O, Jalisi S, Truong MT. A Prognostic volumetric threshold of gross tumor volume in head and neck cancer patients treated with radiotherapy. Am J Clin Oncol. 2014;37:154\u201361. https:\/\/doi.org\/10.1097\/COC.0b013e31826e04d6.","journal-title":"Am J Clin Oncol"},{"key":"2074_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2307\/3577740","volume":"123","author":"M Baumann","year":"1990","unstructured":"Baumann M, DuBois W, Suit HD. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. Radiat Res. 1990;123:325. https:\/\/doi.org\/10.2307\/3577740.","journal-title":"Radiat Res"},{"key":"2074_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/0360-3016(95)00031-S","volume":"32","author":"CR Johnson","year":"1995","unstructured":"Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, Ravalese J, Wazer DE. The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation. Int J Radiat Oncol Biol Phys. 1995;32:635\u201341. https:\/\/doi.org\/10.1016\/0360-3016(95)00031-S.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2074_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0360-3016(95)00119-J","volume":"33","author":"CR Johnson","year":"1995","unstructured":"Johnson CR, Thames HD, Huang DT, Schmidt-Ullrich RK. The tumor volume and clonogen number relationship: Tumor control predictions based upon tumor volume estimates derived from computed tomography. Int J Radiat Oncol Biol Phys. 1995;33:281\u20137. https:\/\/doi.org\/10.1016\/0360-3016(95)00119-J.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2074_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0360-3016(93)90189-3","volume":"26","author":"DJ Brenner","year":"1993","unstructured":"Brenner DJ. Dose, volume, and tumor-control predictions in radiotherapy. Int J Radiat Oncol. 1993;26:171\u20139. https:\/\/doi.org\/10.1016\/0360-3016(93)90189-3.","journal-title":"Int J Radiat Oncol"},{"key":"2074_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0360-3016(00)01559-5","volume":"50","author":"R Hermans","year":"2001","unstructured":"Hermans R, Op de beeck K, Van den Bogaert W, Rijnders A, Staelens L, Feron M, et al. The relation of CT-determined tumor parameters and local and regional outcome of tonsillar cancer after definitive radiation treatment. Int J Radiat Oncol. 2001;50:37\u201345. https:\/\/doi.org\/10.1016\/S0360-3016(00)01559-5.","journal-title":"Int J Radiat Oncol"},{"key":"2074_CR33","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1097\/MLG.0b013e318172c82c","volume":"118","author":"MJ Been","year":"2008","unstructured":"Been MJ, Watkins J, Manz RM, Gentry LR, Leverson GE, Harari PM, et al. Tumor volume as a prognostic factor in oropharyngeal squamous cell carcinoma treated with primary radiotherapy. Laryngoscope. 2008;118:1377\u201382. https:\/\/doi.org\/10.1097\/MLG.0b013e318172c82c.","journal-title":"Laryngoscope"},{"key":"2074_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1097-0347(200001)22:1<1::AID-HED1>3.0.CO;2-6","volume":"22","author":"RM Nathu","year":"2000","unstructured":"Nathu RM, Mancuso AA, Zhu TC, Mendenhall WM. The impact of primary tumor volume on local control for oropharyngeal squamous cell carcinoma treated with radiotherapy. Head Neck. 2000;22:1\u20135. https:\/\/doi.org\/10.1002\/(SICI)1097-0347(200001)22:1%3c1::AID-HED1%3e3.0.CO;2-6.","journal-title":"Head Neck"},{"key":"2074_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/hed.10253","volume":"25","author":"WM Mendenhall","year":"2003","unstructured":"Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Mancuso AA. Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck. 2003;25:535\u201342. https:\/\/doi.org\/10.1002\/hed.10253.","journal-title":"Head Neck"},{"key":"2074_CR36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/hed.25505","volume":"41","author":"T Chotchutipan","year":"2019","unstructured":"Chotchutipan T, Rosen BS, Hawkins PG, Lee JY, Saripalli AL, Thakkar D, et al. Volumetric 18 F-FDG-PET parameters as predictors of locoregional failure in low-risk HPV-related oropharyngeal cancer after definitive chemoradiation therapy. Head Neck. 2019;41:366\u201373. https:\/\/doi.org\/10.1002\/hed.25505.","journal-title":"Head Neck"},{"key":"2074_CR37","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.radonc.2020.10.006","volume":"155","author":"BS Rosen","year":"2021","unstructured":"Rosen BS, Wilkie JR, Sun Y, Ibrahim M, Casper KA, Miller JE, et al. CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Radiother Oncol Elsevier Ireland Ltd. 2021;155:174\u201381. https:\/\/doi.org\/10.1016\/j.radonc.2020.10.006.","journal-title":"Radiother Oncol Elsevier Ireland Ltd"},{"key":"2074_CR38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.radonc.2017.04.004","volume":"124","author":"S Welz","year":"2017","unstructured":"Welz S, M\u00f6nnich D, Pfannenberg C, Nikolaou K, Reimold M, La Foug\u00e8re C, et al. Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiother Oncol. 2017;124:526\u201332. https:\/\/doi.org\/10.1016\/j.radonc.2017.04.004.","journal-title":"Radiother Oncol"},{"key":"2074_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.radonc.2012.09.015","volume":"105","author":"LS Mortensen","year":"2012","unstructured":"Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET\/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiother Oncol. 2012;105:14\u201320. https:\/\/doi.org\/10.1016\/j.radonc.2012.09.015.","journal-title":"Radiother Oncol"},{"key":"2074_CR40","doi-asserted-by":"publisher","unstructured":"Zschaeck S, L\u00f6ck S, Hofheinz F, Zips D, Saks\u00f8 Mortensen L, Z\u00f6phel K, et al. Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. Radiother Oncol. Elsevier B.V.; 2020;149:189\u201396. https:\/\/doi.org\/10.1016\/j.radonc.2020.05.022","DOI":"10.1016\/j.radonc.2020.05.022"},{"key":"2074_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.01470","volume":"9","author":"M van der Heijden","year":"2020","unstructured":"van der Heijden M, Essers PBM, de Jong MC, de Roest RH, Sanduleanu S, Verhagen CVM, et al. Biological determinants of chemo-radiotherapy response in HPV-negative head and neck cancer: a multicentric external validation. Front Oncol. 2020;9:1\u201317. https:\/\/doi.org\/10.3389\/fonc.2019.01470.","journal-title":"Front Oncol"},{"key":"2074_CR42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0167-8140(92)90242-M","volume":"25","author":"JC Horiot","year":"1992","unstructured":"Horiot JC, Le Fur R, N\u2019Guyen T, Chenal C, Schraub S, Alfonsi S, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992;25:231\u201341. https:\/\/doi.org\/10.1016\/0167-8140(92)90242-M.","journal-title":"Radiother Oncol"},{"key":"2074_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0167-8140(97)00079-0","volume":"44","author":"JC Horiot","year":"1997","unstructured":"Horiot JC, Bontemps P, Van Den Bogaert W, Le Fur R, Van Den Weijngaert D, Bolla M, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol. 1997;44:111\u201321. https:\/\/doi.org\/10.1016\/S0167-8140(97)00079-0.","journal-title":"Radiother Oncol"},{"key":"2074_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0167-8140(97)00094-7","volume":"44","author":"S Dische","year":"1997","unstructured":"Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123\u201336. https:\/\/doi.org\/10.1016\/S0167-8140(97)00094-7.","journal-title":"Radiother Oncol"},{"key":"2074_CR45","doi-asserted-by":"publisher","unstructured":"Zhao L, West BT, Hayman JA, Lyons S, Cease K, Kong FM (Spring). High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;68:103\u201310. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.11.051","DOI":"10.1016\/j.ijrobp.2006.11.051"},{"key":"2074_CR46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.radonc.2012.12.008","volume":"106","author":"M Soliman","year":"2013","unstructured":"Soliman M, Yaromina A, Appold S, Zips D, Reiffenstuhl C, Schreiber A, et al. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: Subgroup analysis of the prospective randomized CHARTWEL trial. Radiother Oncol Elsevier Ireland Ltd. 2013;106:299\u2013304. https:\/\/doi.org\/10.1016\/j.radonc.2012.12.008.","journal-title":"Radiother Oncol Elsevier Ireland Ltd"},{"key":"2074_CR47","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","volume":"156","author":"B Lacas","year":"2021","unstructured":"Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol Elsevier Ireland Ltd. 2021;156:281\u201393. https:\/\/doi.org\/10.1016\/j.radonc.2021.01.013.","journal-title":"Radiother Oncol Elsevier Ireland Ltd"},{"key":"2074_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-82999-3","volume":"11","author":"JM Trinh","year":"2021","unstructured":"Trinh JM, Thomas J, Salleron J, Henrot P. Differences in clinical and imaging characteristics between p16-positive non-smokers and p16-positive smokers or p16-negative patients in oropharyngeal carcinoma. Sci Rep Nature Publishing Group UK. 2021;11:1\u201311. https:\/\/doi.org\/10.1038\/s41598-021-82999-3.","journal-title":"Sci Rep Nature Publishing Group UK"},{"key":"2074_CR49","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/hed.24764","volume":"39","author":"MW Chan","year":"2017","unstructured":"Chan MW, Yu E, Bartlett E, O\u2019Sullivan B, Su J, Waldron J, et al. Morphologic and topographic radiologic features of human papillomavirus-related and \u2013unrelated oropharyngeal carcinoma. Head Neck. 2017;39:1524\u201334. https:\/\/doi.org\/10.1002\/hed.24764.","journal-title":"Head Neck"},{"key":"2074_CR50","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ijrobp.2011.05.060","volume":"83","author":"A Thiagarajan","year":"2012","unstructured":"Thiagarajan A, Caria N, Sch\u00f6der H, Iyer NG, Wolden S, Wong RJ, et al. Target volume delineation in oropharyngeal cancer: Impact of PET, MRI, and physical examination. Int J Radiat Oncol Biol Phys. 2012;83:220\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.05.060.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2074_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.radonc.2010.12.010","volume":"100","author":"B Zackrisson","year":"2011","unstructured":"Zackrisson B, Nilsson P, Kjell\u00e9n E, Johansson K, Modig H, Brun E, et al. Two-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma\u2013the ARTSCAN study. Radiother Oncol. 2011;100:41\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2010.12.010.","journal-title":"Radiother Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02074-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T06:22:29Z","timestamp":1655187749000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02074-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2074"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02074-7","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical boards approved the three studies as previously described [\n                      \n                      ,\n                      \n                      ,\n                      \n                      ].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}